

Oncoinvent

Transforming cancer care through direct alpha therapy

First quarter business update

29 April 2026

Disclaimer and important information



This presentation (the “Presentation”) has been prepared by Oncoinvent ASA (the “Company”) for information purposes only and does not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities of the Company in any jurisdiction. Any securities of the Company may not be offered or sold except pursuant to applicable law and in accordance with applicable registration requirements or exemptions therefrom.

This Presentation is not intended to be, and should not be construed as, legal, tax, investment or other advice. Recipients should consult their own advisers as to the legal, tax, financial, investment and other matters contained herein. By attending a meeting where this Presentation is made and/or by reading these materials, you acknowledge that you are solely responsible for your own assessment of the Company and the information contained in this Presentation.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information contained in this Presentation. Certain information in this Presentation has not been independently verified. The information contained herein is subject to change without notice and the Company does not undertake any obligation to update or revise this Presentation, whether as a result of new information, future events or otherwise, except as required by applicable law.

This Presentation contains forward-looking statements, including, without limitation, statements regarding the Company’s strategy, plans, objectives, milestones, clinical development activities, timelines, trial design and outcomes, regulatory interactions, manufacturing and supply chain readiness, partnering intentions, market opportunity, and expected financial performance and cash runway. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others: the inherent uncertainty in drug development; the ability to initiate, conduct and complete preclinical and clinical studies and obtain expected data within anticipated timelines; patient recruitment and retention; clinical trial site activation and operational execution; safety, tolerability and efficacy outcomes; regulatory review, communications and approvals; changes in applicable laws, regulations and regulatory guidance; manufacturing, quality and supply chain risks (including availability of radionuclides, production capacity, validation and compliance with GMP requirements); reliance on third parties and suppliers; intellectual property protection and freedom to operate; competitive developments; the ability to obtain, maintain and enforce patents and other rights; the ability to enter into and maintain collaborations and partnerships on acceptable terms; pricing, reimbursement and market adoption; and the Company’s ability to raise additional financing when needed. Additional risks and uncertainties are described in the Company’s publicly available disclosures from time to time.


Nothing in this Presentation is intended to be, or should be construed as, medical advice, a diagnosis, or a recommendation regarding any treatment. Any product candidates referenced are investigational and have not been approved for marketing by any regulatory authority, and their safety and efficacy have not been established.

Certain financial and other measures included in this Presentation may not be prepared in accordance with IFRS and may be alternative performance measures (“APMs”). Such measures may not be comparable to similarly titled measures presented by other companies. Definitions and reconciliations, if any, should be read together with the Company’s financial reporting.

The distribution of this Presentation may be restricted by law in certain jurisdictions, and persons into whose possession it comes should inform themselves about, and observe, any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of any such jurisdiction.

This Presentation speaks as of 29 April 2026. The Company undertakes no obligation to update it except as required by applicable law.


Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy




Micrometastases

Cancer in the abdominal cavity is an area with **high unmet need** and few good treatment options

Oncoinvent: aiming to transform cancer care for patients through direct alpha therapy



Cancer in the abdominal cavity is an area with **high unmet need** and few good treatment options



Oncoinvent develops Radspherin®, a receptor-independent alpha radiopharmaceutical that **eradicates cancer cells in the abdominal cavity after surgery** with a single, targeted dose.

Ongoing clinical development



Completed

Upcoming milestones

Recent Highlights

Radspherin®

- Recruited and **randomized a total of 37 patients** (accumulated, ITT*) into the ovarian Phase 2 trial
- Secured **new patent** expanding protection for Radspherin®
- Published **positive final data** from Phase 1 trial of Radspherin® to treat **ovarian cancer**
 - Journal: Gynecologic Oncology
 - Conference: ESGO European Gynaecological Oncology Congress 2026

Corporate

- Appointed Dr Ramzi Amri as **CFO**

Good recruitment momentum so far in 2026

Progress so far


- A total of **37 patients** per 'intention to treat' have been recruited and randomized by end March
- **Best quarter to date:** Good recruitment momentum so far in 2026
- **Ten hospitals** are active. In addition to the original six, new hospitals have been added in Italy, UK and Spain (2)



The way ahead

- **Additional hospitals** will be added
- Selected **protocol amendments** are all approved and starting to show effect
- Patient-centered **online tool** with trial information and 'pre-screener'

Recruitment momentum is picking up



Key facts:

- Q1 2026 best month so far in terms of patients recruited
- At current pace, Q2 trending well

Six initial safety patients were included prior to randomization

Guiding on cash

Cash position

- As of March 31, 2026, cash and cash equivalents totaled approximately **NOK 130 million**

Cash runway

- Based on the current operating plan and anticipated expenditures, Oncoinvent continues to expect that its existing cash resources will be sufficient to fund operations **into 2027**

Outlook

- While Oncoinvent anticipates Clinical R&D expenses associated with advancing clinical programs to scale in proportion to recruitment, it remains committed to disciplined financial management. **No material changes to operating cash burn** are expected in the near term compared to prior periods.
- The company continues to explore potential strategic options to **extend its cash runway further**, including business development initiatives, partnerships, and potential financing opportunities

Why I joined Oncoinvent



Why I joined Oncoinvent

Patient need I know...

- Medical and Surgical Oncology background made the **impact of peritoneal metastasis very tangible**
- For patients, this often meant:
 - **Poor prognosis**
 - Very high **recurrence**
 - **Quality-of-life** burden



...a product rationale I believe in

- Radspherin® is designed to **address** a clear **clinical failure point**: microscopic residual disease in the peritoneal cavity after surgery
- Local alpha therapy is well suited to a local residual-disease problem
- Designed as a **low-burden addition** to the existing treatment pathway



...a place where I can add value

- Mission-driven team addressing a **serious unmet need**
- Rare fit with my medical, oncology, strategic, and financial background
- Company stage where execution, financing, partnerships, and narrative can materially shape the outcome

Financial Calendar

Today	Q1 update and presentation
20 May	Annual General Meeting
27 August	H1 report and presentation
28 October	Q3 update and presentation